The global avascular necrosis market size is expected to reach USD 809.5 Mn in 2026 and is projected to grow at a CAGR of 6.0% during the forecast period (2026-2033), surpassing USD 1,216.9 Mn by 2033.
The avascular necrosis market will be propelled by the increasing prevalence of osteonecrosis that results from corticosteroid therapy, trauma, sickle cell anemia, alcoholism, and autoimmune conditions. Growing awareness levels and availability of better diagnostic imaging methods will contribute to the early detection and management of the disease. An aging population base, along with the increased prevalence of inflammatory conditions, will also drive market growth. Nevertheless, late diagnosis of the disease, limited availability of disease-modifying drugs, and high costs of surgical procedures are some of the challenges faced by this market.
Based on Drug Type, the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is likely to lead the market, capturing a market share of 38.0% by 2026. The dominance of this segment is due to the extensive use of NSAIDs such as ibuprofen and naproxen as the primary form of treatment for pain and inflammation in avascular necrosis. The affordability, easy accessibility, ease of use, and effectiveness of the drugs in increasing mobility have increased their use.
Based on Route of Administration, the Oral segment is expected to hold a market share of 68.0% by 2026. The oral form of medication provides ease in use, higher efficiency, better compliance, and cost-effectiveness. It is still considered the preferred method for conservative treatment of avascular necrosis.
Geographically, North America is anticipated to lead the avascular necrosis market, contributing to around 39.0% market share in 2026, owing to superior healthcare facilities, high usage of corticosteroids, high awareness regarding musculoskeletal disorders, superior access to prescription drugs, and growing cases of avascular necrosis. The Asia Pacific region is likely to witness the highest growth in the global avascular necrosis market, contributing to around 24.0% of the market in 2026, due to high patient population, rising prevalence of sickle cell disease, growing healthcare infrastructure, rising use of corticosteroids for chronic illnesses, and improved access to orthopedic treatments in India and China.
Prominent Players in the Avascular Necrosis Market
-
Teva Pharmaceutical Industries Ltd.
Company Overview
- Headquarters: Tel Aviv, Israel
- Establishment Year: 1901
- Employee Strength: Approximately 36,000 employees
- Leadership: Mr. Richard Francis, President & Chief Executive Officer
- Core Services/Products: Generic pharmaceuticals, specialty medicines, pain management therapies, anti-inflammatory drugs (NSAIDs), central nervous system treatments, and active pharmaceutical ingredients.
SWOT Analysis
- Strengths
- Global market leader of generic medicines with an extensive range of NSAIDs.
- Wide manufacturing and distribution channels in all important healthcare markets.
- Weaknesses
- Highly reliant on competitive generic medicines market.
- Facing risks due to pricing and patents expiring.
- Opportunities
- Increasing requirement of cheap pain management medicines.
- Selling in developing markets with rising cases of chronic diseases.
- Threats
- Compliance with regulatory guidelines.
- Increased competition among global generic pharmaceutical firms.
-
Dr. Reddy’s Laboratories Ltd.
Company Overview
- Headquarters: Hyderabad, Telangana, India
- Establishment Year: 1984
- Employee Strength: Approximately 26,000 employees
- Leadership: Mr. Erez Israeli, Chief Executive Officer
- Core Services/Products: Generic medicines, active pharmaceutical ingredients (APIs), biosimilars, anti-inflammatory drugs, pain management products, and specialty pharmaceuticals.
SWOT Analysis
- Strengths
- Wide international footprint with generics and APIs.
- Broad research expertise with varied therapeutics range.
- Weaknesses
- Heavy dependence on regulatory market revenues.
- Susceptibility to pricing pressures in generics market.
- Opportunities
- Higher demand for economically priced musculoskeletal drugs.
- Developing specialty pharmaceutical products in developing nations.
- Threats
- Growing competition from low-cost generics producers.
- Compliance risks with regulatory inspections.
-
Solara Active Pharma Sciences Limited
Company Overview
- Headquarters: Chennai, Tamil Nadu, India
- Establishment Year: 2017
- Employee Strength: Approximately 3,500 employees
- Leadership: Mr. R. Shankar, Managing Director & Chief Executive Officer
- Core Services/Products: Active pharmaceutical ingredients (APIs), contract manufacturing, anti-inflammatory APIs, analgesic ingredients, and specialty pharmaceutical intermediates.
SWOT Analysis
- Strengths
- Expertise in API production.
- Versatile product range catering to the pharmaceutical industry worldwide.
- Weaknesses
- More focused on the API production side rather than finished formulations.
- Revenue is influenced by price fluctuations of the raw materials.
- Opportunities
- The increase in API production outsourcing to the global market.
- The rising need for pharmaceutical intermediates.
- Threats
- Extensive competition among API manufacturers in Asia.
- Compliance issues.
-
Bayer AG
Company Overview
- Headquarters: Leverkusen, Germany
- Establishment Year: 1863
- Employee Strength: Approximately 93,000 employees
- Leadership: Mr. Bill Anderson, Chief Executive Officer
- Core Services/Products: Prescription medicines, consumer health products, pain management therapies, anti-inflammatory medicines, cardiovascular drugs, and pharmaceutical research.
SWOT Analysis
- Strengths
- World-renowned healthcare brand with a diversified drug portfolio.
- Effective research and development initiatives due to global operations.
- Weaknesses
- Extensive operational complications due to diversified operations.
- Vulnerability to lawsuits and regulation.
- Opportunities
- Increasing requirement of drugs for treatment of musculoskeletal pain.
- Increasing production of over-the-counter analgesics and anti-inflammatory drugs.
- Threats
- Patent expiry and generic entry.
- Business risks in terms of pricing and reimbursement.
-
Rochem International Inc.
Company Overview
- Headquarters: New York, U.S.
- Establishment Year: 1994
- Employee Strength: Approximately 100 employees
- Leadership: Mr. Richard R. Wurth, President
- Core Services/Products: Pharmaceutical sourcing, active pharmaceutical ingredients (APIs), specialty chemicals, supply chain management, and global pharmaceutical distribution.
SWOT Analysis
- Strengths
- Great expertise in global sourcing of pharmaceutical products and supply chains.
- Flexible supply chain network for pharmaceutical manufacturers in all parts of the world.
- Weaknesses
- Being smaller in scale than multinational pharmaceutical companies.
- Reliance on manufacturing partners.
- Opportunities
- Increasing demand for reliable sources of API and pharmaceuticals supply.
- Entering new pharmaceutical markets.
- Threats
- Risks associated with logistics and geopolitical situation.
- More competition from global pharmaceutical distributors.
